Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Other Operating Expenses (2016 - 2021)

Historic Other Operating Expenses for BioRestorative Therapies (BRTX) over the last 11 years, with Q4 2021 value amounting to $87282.0.

  • BioRestorative Therapies' Other Operating Expenses rose 14208.02% to $87282.0 in Q4 2021 from the same period last year, while for Sep 2022 it was $87282.0, marking a year-over-year increase of 5894.89%. This contributed to the annual value of $87282.0 for FY2021, which is 4727.15% down from last year.
  • As of Q4 2021, BioRestorative Therapies' Other Operating Expenses stood at $87282.0, which was up 14208.02% from $7868.0 recorded in Q2 2021.
  • In the past 5 years, BioRestorative Therapies' Other Operating Expenses registered a high of $884362.0 during Q2 2017, and its lowest value of $7868.0 during Q2 2021.
  • For the 5-year period, BioRestorative Therapies' Other Operating Expenses averaged around $371267.6, with its median value being $482574.0 (2017).
  • In the last 5 years, BioRestorative Therapies' Other Operating Expenses plummeted by 9382.13% in 2020 and then skyrocketed by 14208.02% in 2021.
  • Over the past 5 years, BioRestorative Therapies' Other Operating Expenses (Quarter) stood at $491195.0 in 2017, then skyrocketed by 50.82% to $740833.0 in 2018, then dropped by 28.44% to $530154.0 in 2019, then tumbled by 93.2% to $36055.0 in 2020, then surged by 142.08% to $87282.0 in 2021.
  • Its last three reported values are $87282.0 in Q4 2021, $7868.0 for Q2 2021, and $10989.0 during Q1 2021.